These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

250 related items for PubMed ID: 19852531

  • 1. Lanthanum carbonate: a review of its use in lowering serum phosphate in patients with end-stage renal disease.
    Curran MP, Robinson DM.
    Drugs; 2009 Nov 12; 69(16):2329-49. PubMed ID: 19852531
    [Abstract] [Full Text] [Related]

  • 2. A comparative study of phosphate binders in patients with end stage kidney disease undergoing hemodialysis.
    Prajapati VA, Galani VJ, Shah PR.
    Saudi J Kidney Dis Transpl; 2014 May 12; 25(3):530-8. PubMed ID: 24821148
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Efficacy of continuous oral administration of lanthanum carbonate over 24 months.
    Ishizu T, Hong Z, Matsunaga T, Kaneko Y, Taru Y.
    Ther Apher Dial; 2013 Apr 12; 17 Suppl 1():22-8. PubMed ID: 23586509
    [Abstract] [Full Text] [Related]

  • 5. A meta-analysis of phosphate binders lanthanum carbonate versus sevelamer hydrochloride in patients with end-stage renal disease undergoing hemodialysis.
    Zhou T, Li H, Xie W, Lin Z.
    Afr Health Sci; 2018 Sep 12; 18(3):689-696. PubMed ID: 30603002
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Lanthanum carbonate (Fosrenol) efficacy and tolerability in the treatment of hyperphosphatemic patients with end-stage renal disease.
    Chiang SS, Chen JB, Yang WC.
    Clin Nephrol; 2005 Jun 12; 63(6):461-70. PubMed ID: 15960148
    [Abstract] [Full Text] [Related]

  • 9. Sevelamer hydrochloride: a review of its use for hyperphosphataemia in patients with end-stage renal disease on haemodialysis.
    Goldsmith DR, Scott LJ, Cvetković RS, Plosker GL.
    Drugs; 2008 Jun 12; 68(1):85-104. PubMed ID: 18081374
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Lanthanum carbonate.
    Swainston Harrison T, Scott LJ.
    Drugs; 2004 Jun 12; 64(9):985-96; discussion 997-8. PubMed ID: 15101790
    [Abstract] [Full Text] [Related]

  • 15. Lanthanum carbonate for hyperphosphatemia in patients on peritoneal dialysis.
    Ohno M, Ohashi H, Oda H, Yokoyama H, Okada M, Nagaya M, Izumi K, Ito H, Katoh S.
    Perit Dial Int; 2013 Jun 12; 33(3):297-303. PubMed ID: 23209037
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Lanthanum carbonate effectively controls serum phosphate without affecting serum calcium levels in patients undergoing hemodialysis.
    Shigematsu T, Lanthanum Carbonate Research Group.
    Ther Apher Dial; 2008 Feb 12; 12(1):55-61. PubMed ID: 18257813
    [Abstract] [Full Text] [Related]

  • 18. Three-year follow-up of lanthanum carbonate therapy in hemodialysis patients.
    Takeuchi K, Matsuda E, Sekino M, Hasegawa Y, Kamo Y, Kikuchi N, Sekino H.
    Ther Apher Dial; 2013 Apr 12; 17 Suppl 1():15-21. PubMed ID: 23586508
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.